Previous studies have found that the use of PD-1, PD-L1, and CTLA4 inhibitors can have a better immune effect on refractory (MSI-H and MSS) colorectal tumors [23, 24], but the recurrence and adverse reactions have been reported in the number of patients. Here, PDCD1 is linked to colorectal neoplasm.